# US 2008/0313750 A1 · Transgenic Non-Human Animal Model of Lung Tumorigenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0313750 A1
- Document ID: US20080313750A1
- Status: Published application
- Kind: A1
- Application number: 11/996,003
- Filed: 2006-07-28
- Published: 2008-12-18
- Earliest claimed: 2005-07-28
- Assignees: Trustees of Dartmouth College
- Inventors: Ethan Dmitrovsky; Yan Ma; Sarah J. Freemantle
- Web page: https://patentgrep.com/patent/US20080313750A1

## CPC

- C07K 14/4738: {Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR (cell cycle dependent kinases C12N9/12)}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is a transgenic non-human animal whose genome contains a transgene containing a nucleic acid encoding a cyclin E protein operably linked to a regulatory element including a lung-specific promoter. The transgenic animals of the present invention have elevated levels cyclin E protein in the lung and have in increased occurrence of lung carcinogenesis. The animals of the instant invention were also found to have increased levels of Gli1 and Shh. Vectors, cells and cell lines are provided, as is a method for identifying a therapeutic agent for the chemoprevention or treatment of lung cancer.

## Claims

### Claim 1

A transgenic non-human animal whose genome contains a transgene comprising a nucleic acid encoding a cyclin E protein operably linked to a regulatory element comprising a lung-specific promoter so that cyclin E protein levels are elevated in the lung of the animal thereby promoting lung carcinogenesis.

### Claim 2 (depends on 1)

The transgenic non-human animal of claim 1, wherein the animal is subject to a second stimulus which promotes lung carcinogenesis.

### Claim 3 (depends on 1)

The transgenic non-human animal of claim 1, wherein the cyclin E protein expressed by the animal is degradation resistant.

### Claim 4 (depends on 1)

A cell or cell line isolated from the transgenic non-human animal of claim 1.

### Claim 5

A vector containing a transgene comprising a nucleic acid encoding a cyclin E protein operably linked to a regulatory element comprising a lung-specific promoter.

### Claim 6 (depends on 1, 2)

A method for identifying a therapeutic agent for the chemoprevention or treatment of lung cancer comprising
administering a test agent or combination of test agents to a transgenic non-human animal of claim 1 or claim 2, and
determining whether the signs or symptoms associated with lung cancer are prevented, delayed or treated in the transgenic non-human animal thereby identifying a therapeutic agent for the chemoprevention or treatment of lung cancer.

### Claim 7 (depends on 4)

A method for identifying a therapeutic agent for the chemoprevention or treatment of lung cancer comprising
contacting the cell or cell line of claim 4 with a test agent or combination of test agents, and
determining whether the test agent decreases the expression or activity of cyclin E, Gli1 or Shh in the cell or cell line thereby identifying a therapeutic agent for the chemoprevention or treatment of lung cancer.
